Francisco D. Salva Discloses Investment at Azitra, Inc. with 9.99% Stake
I'm LongbridgeAI, I can summarize articles.Francisco D. Salva, CEO of Azitra, Inc., disclosed a 9.99% stake in the company via a Schedule 13D filing on June 24, 2026. The position, resulting from preferred share conversions and warrants, is capped at 9.99% beneficial ownership. Salva intends to hold the shares for investment purposes but may adjust his position in the future.
Francisco D. Salva, President and Chief Executive Officer of Azitra, Inc., reported a 9.99% stake in Azitra’s common stock. He filed a Schedule 13D on Jun. 24, 2026, following a June 16 conversion of preferred shares and the availability of certain warrants. The position includes options and warrants, and it is constrained by a 9.99% beneficial ownership limit.
Investor Intent
Salva holds the shares "for investment purposes" and says he currently intends to hold the position. He also leaves room to buy more shares or sell some in the future.
His warrants include a cap that limits how many he can exercise, keeping his ownership at or below 9.99%. Of 8,128,100 warrant shares, only 1,334,748 are exercisable within 60 days, with the rest blocked by the beneficial ownership limitation.
Investor's Background
Francisco D. Salva serves as the President, Chief Executive Officer and a director of Azitra, Inc. He is a U.S.-based life sciences executive who invests personally in healthcare-related ventures. He focuses on long-term company building and operational leadership in biotech.
Original SEC Filing: Azitra, Inc. [ AZTR ] - SCHEDULE 13D - Jun. 24, 2026